Journal article
Randomized controlled trial reveals no benefit to a 3-month delay in COVID-19 mRNA booster vaccine
WS Lee, J Audsley, MC Trieu, A Reynaldi, LC Aurelia, PH Mehta, J Patterson, HE Kent, J Nguyen, T Amarasena, R Esterbauer, ER Haycroft, P Ramanathan, MP Davenport, TE Schlub, J Sasadeusz, AK Wheatley, AW Chung, JA Juno, KJ Selva Show all
Journal of Clinical Investigation | Published : 2024
DOI: 10.1172/JCI181244
Abstract
BACKGROUND. There is uncertainty about the timing of booster vaccination against COVID-19 in highly vaccinated populations during the present endemic phase of COVID-19. Studies focused on primary vaccination have previously suggested improved immunity with a longer interval between the first and second vaccine doses. METHODS. We conducted a randomized, controlled trial (November 2022-August 2023) and assigned 52 fully vaccinated adults to an immediate or a 3-month delayed bivalent Spikevax mRNA booster vaccine. Follow-up visits were completed for 48 participants (n = 24 per arm), with collection of saliva and plasma samples following each visit. RESULTS. The rise in neutralizing antibody res..
View full abstractGrants
Awarded by University of Melbourne
Funding Acknowledgements
National Health and Medical Research Council, Australia (program grant App1149990) and Medical Research Future Fund (App2005544).